India’s drug regulator CDSCO has tightened rules for drug safety reporting. Pharma firms must file safety reports starting from the actual launch date of new drugs rather than the approval date. The regulator says this will better capture real-world safety signals. It also brings all forms and uses of a new drug under one consolidated safety report.
India’s appetite for weight-loss injectables like Ozempic and Mounjaro is rising fast, with consumers seeking gradual weight reduction. But healthcare professionals are warning that the current regulatory and marketing environment is not keeping pace, increasing the risk of misuse and improper promotion. Calls are growing for stronger oversight to protect patients.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
